WNK2 and melanoma: Approximately 50% of melanomas have BRAF mutations, with the majority being BRAFV600E, which causes intrinsic activation of the BRAF-MEK-ERK-MAPK signalling pathway, also known as the Mitogen-activated protein kinase (MAPK) pathway [7,8], leading to enhanced melanoma cell proliferation and survival [7].